Loading...
NPI 1376206425 · North Little Rock, AR · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Infinite Genomics LLC is a clinical medical laboratory provider located in North Little Rock, Arkansas. This profile covers 24 Medicare and 34 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Infinite Genomics LLC |
| Address | 4850 Northshore Ln |
| City | North Little Rock |
| State | AR |
| ZIP | 72118 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 15, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $2M |
| Medicare | $1.9M |
INFINITE GENOMICS LLC bills to both Medicare and Medicaid at a similar scale: total Medicare revenue is $1.9M while total Medicaid revenue is $2M, making the practice effectively a dual-payer operation rather than single-payer dependent. The near-parity in dollars suggests the lab draws comparable volume from both programs rather than being concentrated exclusively in one payer.
Medicare revenue is highly concentrated: the precomputed top three Medicare codes account for 82.2% of Medicare revenue, driven by 87798 (51.1%), 87801 (23.0%), and 87481 (8.1%). This concentration indicates that a small set of molecular infectious-disease assays dominates the provider’s Medicare billing.
The provider’s code mix points to a specialized molecular diagnostics operation focused on nucleic acid amplified probe testing. High-revenue codes on both payers — including 87798, 87801, and 87481 on Medicare and 87798, U0003, and 87801 on Medicaid — are all infectious-agent nucleic acid detection tests (many using amplified probe techniques), and Medicaid activity also includes high-throughput SARS‑CoV‑2 testing (U0003), signaling capacity for high-volume molecular and COVID-era workflows.
On Medicare this lab is a strong national participant for several molecular codes: 87798 is reported at rank #65 of 1319 providers nationally (95th percentile; typical, unremarkable volume for this code), 87801 ranks #14 of 561 (98th percentile; typical, unremarkable volume for this code), and 87481 ranks #79 of 1117 (93th percentile; typical, unremarkable volume for this code). While the dataset’s plain-English labels call these volumes "typical, unremarkable," the percentile and ranking positions indicate the provider sits toward the upper end of national billing volume for these molecular tests.
Within Arkansas Medicaid the provider shows stronger in‑state positioning on key assays: 87798 ranks #4 of 30 in-state (90th percentile; typical, unremarkable volume for this code), 87801 ranks #2 of 15 (93th percentile; typical, unremarkable volume for this code), and U0003 ranks #16 of 81 (81th percentile; typical, unremarkable volume for this code). The provider also appears as a state-level outlier on certain tests that are explicitly labeled "notably above typical state volume for this code," including 87498 (rank #1 of 5) and 87541 (rank #1 of 6), indicating pockets of unusually high in-state volume for specific diagnostic assays.
Medicaid revenue shows a different concentration profile: the precomputed top three Medicaid codes account for 51.4% of Medicaid revenue with 87798 alone responsible for 37.5% of Medicaid revenue. Notably, 87798 also attracts much higher Medicaid unit payments than Medicare for the same code ($161 avg paid/claim on Medicaid versus $34 avg paid/claim on Medicare), highlighting both clinical concentration on this assay and material payer-rate differences that shape revenue.
The NPI tenure is recent relative to many labs: the provider was enumerated on 2021-10-15 (~5 years ago). This relatively short operational history, combined with high revenue concentration in a few molecular assays, suggests growth to date has been driven by a focused molecular testing footprint and that future volatility in these assay lines or payer policy could materially affect revenue.
From an operational and contract perspective the provider’s concentration in a narrow set of amplified nucleic acid probe tests creates sensitivity to reimbursement or referral shifts: Medicare’s top three codes account for 82.2% of Medicare revenue and Medicaid’s top three account for 51.4% of Medicaid revenue, so changes in utilization, reimbursement, or network contracting for a small number of codes could have outsized financial impact. Analysts should flag dependence on 87798 across both payers and on high-throughput SARS‑CoV‑2 testing (U0003) on Medicaid when assessing contracting or risk scenarios.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
24 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 28,610 | $30 | $972.8K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 6,330 | $70 | $436.8K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 4,530 | $30 | $153.9K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 2,210 | $30 | $75K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 1,880 | $30 | $64K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 1,690 | $30 | $57.4K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 170 | $140 | $24.1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 280 | $70 | $21K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 610 | $30 | $20.8K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 490 | $30 | $16.8K |
Showing 1–10 of 24
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
34 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4,570 | $160 | $735.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3,680 | $40 | $140K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 1,800 | $70 | $133.1K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2,640 | $50 | $131.8K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 3,490 | $20 | $83.7K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,070 | $70 | $79.5K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 2,800 | $20 | $64.5K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 950 | $70 | $62.8K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 3,300 | $20 | $62.6K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 2,210 | $20 | $44.3K |
Showing 1–10 of 34
How this provider's Medicaid billing volume and revenue compare to other Arkansas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Arkansas median
34 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 28 | 30 | 290 | $240 | $857.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4 | 30 | 160 | $70 | $259.6K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 6 | 20 | 340 | $40 | $197.3K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 6 | 20 | 420 | $40 | $192.3K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 26 | 70 | 830 | $40 | $146.4K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 25 | 70 | 830 | $40 | $144.9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 16 | 80 | 470 | $70 | $139.2K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 9 | 30 | 400 | $40 | $112.1K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 77 | 90 | 510 | $40 | $105.7K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 28 | 110 | 600 | $40 | $95.8K |
Showing 1–10 of 34
Other providers in the same ZIP code as Infinite Genomics LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Med South Medical Inc | AR | Parenteral & Enteral Nutrition Supplies (DME) | $0 | $21M |
| Advanced Pathology Solutions, PLLC | AR | Clinical Medical Laboratory | $14.1M | $4.6M |
| Orthotics At Home, Inc | AR | Customized Equipment (DME) | $0 | $10.9M |
| Scalia Otr/l, Inc. | AR | Occupational Therapist | $0 | $3.8M |
| Alptp, PLLC | AR | Pediatric Occupational Therapist | $0 | $2.7M |
| William Bowen | AR | Orthopaedic Surgery Physician | $530.8K | $0 |
| Paul Edwards | AR | Adult Reconstructive Orthopaedic Surgery Physician | $369.2K | $0 |
| William Hefley | AR | Orthopaedic Surgery Physician | $357.8K | $0 |
| Brad Thomas | AR | Neurological Surgery Physician | $352.9K | $0 |
| Samuel Moore | AR | Orthopaedic Surgery Physician | $331.5K | $1.6K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.